logo-loader
viewShield Therapeutics PLC

Shield Therapeutics: US Partnering Discussions Nearing Fruition

In its recent business and trading update Shield Therapeutics (STX) underlined that the US partnering discussions are progressing, which is a key factor given that the US represents around 70% of the US$3bn global iron replacement market. Therefore, this event can potentially more than double the addressable market for oral iron replacement Feraccru. While there is an ongoing review into the AEGIS-H2H 12-week trial data, longer-term 52-week study data support Feraccru’s efficacy profile, as well as data from two pivotal clinical studies. The balance sheet was recently bolstered by an US$11.4mln milestone payment from China partner ASK Pharm, providing liquidity in the months ahead to negotiate potential uncertainty owing to the coronavirus crisis.

 

Quick facts: Shield Therapeutics PLC

Price: 91.99999 GBX

LSE:STX
Market: LSE
Market Cap: £107.81 m
Follow

What's in the report?

Financial results and forecasts
Growth drivers
Management
Market conditions
Milestones & inflection points

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Shield Therapeutics PLC named herein, including the promotion by the Company of Shield Therapeutics PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

LEGAL NOTICE – IMPORTANT – PLEASE READ:

Proactive Research is a trading name of Proactive Investors Limited which is regulated and authorised by the Financial Conduct Authority (FCA) under firm registration...

FOR OUR FULL DISCLAIMER CLICK HERE

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

Watch

Shield Therapeutics: 'US talks ongoing with progress being made'

Proactive Research analyst Emma Ulker says US partnering discussions at Shield Therapeutics (LON:STX) are progressing and it's a key factor given that the US represents around 70% of the US$3bn global iron replacement market. Ulker adds that the balance sheet was recently bolstered by an...

on 6/5/20

5 min read